The Trial of Monoclonal Antibodies

The Trailblazer All2 study titrated the duration of treatment to PET scans. Amyloid PET scans were conducted at 24 weeks and again at 52 weeks. If patients had actually demonstrated that amyloid plaque had been cleared on the PET scan, they were transitioned from active treatment to placebo.